Background Despite increased interest in mesenchymal stromal cell (MSC)-based cell
therapies for acute respiratory distress syndrome (ARDS), clinical investigations have not yet …

Sepsis and acute respiratory distress syndrome (ARDS) constitute devastating conditions
with high morbidity and mortality. Sepsis results from abnormal host immune response, with …

Rationale: Early post injury mitigation strategies in ARDS are in short supply. Treatments
with allogeneic stromal cells are administered after ARDS develops, require specialized …

The coronavirus SARS-CoV-2 is cause of a global pandemic of a pneumonia-like disease
termed Coronavirus Disease 2019 (COVID-19). COVID-19 presents a high mortality rate …

Extracellular vesicles (EVs) are widely recognized as intercellular communication mediators.
Among the different biological processes, EVs play a role in viral infections, supporting virus …

Mesenchymal stromal cells (MSCs) were identified more than 50 years ago, and research
advances have promoted the translation of pre-clinical studies into clinical settings in …

Background We previously reported a Phase 1/2 randomized placebo-controlled trial of
systemic administration of bone marrow-derived allogeneic MSCs (remestemcel-L) in …

Emerging cellular and pharmacologic therapies for acute resp... : Current Opinion in Critical
Care Emerging cellular and pharmacologic therapies for acute respiratory distress syndrome …

Respiratory diseases remain a major health concern worldwide because they subject
patients to considerable financial and psychosocial burdens and result in a high rate of …

The growing interest in mesenchymal stromal cell (MSC) therapy has been leading to the
utilization of its therapeutic properties in a variety of inflammatory diseases. The clinical …